LT3370760T - Pakaitinė plazminogeno terapija, skirta plazminogeno stokos gydymui - Google Patents

Pakaitinė plazminogeno terapija, skirta plazminogeno stokos gydymui

Info

Publication number
LT3370760T
LT3370760T LTEPPCT/IB2016/001599T LTIB2016001599T LT3370760T LT 3370760 T LT3370760 T LT 3370760T LT IB2016001599 T LTIB2016001599 T LT IB2016001599T LT 3370760 T LT3370760 T LT 3370760T
Authority
LT
Lithuania
Prior art keywords
plasminogen
deficiency
replacement therapy
therapy
replacement
Prior art date
Application number
LTEPPCT/IB2016/001599T
Other languages
English (en)
Lithuanian (lt)
Inventor
Martin Robitaille
Karen Thibaudeau
Pierre Laurin
Stacy PLUM
Original Assignee
Kedrion Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kedrion Biopharma Inc. filed Critical Kedrion Biopharma Inc.
Publication of LT3370760T publication Critical patent/LT3370760T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/IB2016/001599T 2015-11-03 2016-11-03 Pakaitinė plazminogeno terapija, skirta plazminogeno stokos gydymui LT3370760T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (1)

Publication Number Publication Date
LT3370760T true LT3370760T (lt) 2025-12-29

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2016/001599T LT3370760T (lt) 2015-11-03 2016-11-03 Pakaitinė plazminogeno terapija, skirta plazminogeno stokos gydymui

Country Status (24)

Country Link
US (1) US11291711B2 (https=)
EP (1) EP3370760B1 (https=)
JP (1) JP6878423B2 (https=)
KR (1) KR102821400B1 (https=)
CN (1) CN108289935A (https=)
AU (1) AU2016347863B2 (https=)
BR (1) BR112018008965A8 (https=)
CA (1) CA3002915C (https=)
DK (1) DK3370760T3 (https=)
ES (1) ES3055824T3 (https=)
FI (1) FI3370760T3 (https=)
IL (1) IL258913B (https=)
LT (1) LT3370760T (https=)
MX (1) MX2018005588A (https=)
MY (1) MY199581A (https=)
PL (1) PL3370760T3 (https=)
PT (1) PT3370760T (https=)
RS (1) RS67519B1 (https=)
RU (1) RU2736831C2 (https=)
SI (1) SI3370760T1 (https=)
SM (1) SMT202500451T1 (https=)
TW (1) TWI801331B (https=)
WO (1) WO2017077380A1 (https=)
ZA (1) ZA201802820B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CA3008185C (en) * 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
TWI624268B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
WO2018107688A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113597313A (zh) 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (https=) 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
EP0682700A4 (en) * 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
AU2007290881B2 (en) * 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
US20100028321A1 (en) * 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN103221070B (zh) * 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
WO2017101870A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法

Also Published As

Publication number Publication date
EP3370760A4 (en) 2019-06-26
DK3370760T3 (da) 2025-12-22
ES3055824T3 (en) 2026-02-16
WO2017077380A1 (en) 2017-05-11
KR102821400B1 (ko) 2025-06-18
PT3370760T (pt) 2025-12-03
SI3370760T1 (sl) 2026-02-27
RU2736831C2 (ru) 2020-11-20
SMT202500451T1 (it) 2026-01-12
IL258913A (en) 2018-06-28
BR112018008965A8 (pt) 2019-02-26
US11291711B2 (en) 2022-04-05
MY199581A (en) 2023-11-07
CA3002915C (en) 2024-01-16
TWI801331B (zh) 2023-05-11
CA3002915A1 (en) 2017-05-11
ZA201802820B (en) 2019-07-31
EP3370760B1 (en) 2025-10-01
NZ742657A (en) 2024-04-26
PL3370760T3 (pl) 2026-03-23
JP2018533589A (ja) 2018-11-15
TW201722463A (zh) 2017-07-01
AU2016347863A1 (en) 2018-06-07
AU2016347863B2 (en) 2023-11-09
RS67519B1 (sr) 2025-12-31
BR112018008965A2 (pt) 2018-11-21
RU2018120182A3 (https=) 2020-04-27
JP6878423B2 (ja) 2021-05-26
IL258913B (en) 2021-12-01
KR20180083348A (ko) 2018-07-20
US20190231854A1 (en) 2019-08-01
FI3370760T3 (fi) 2025-12-05
MX2018005588A (es) 2018-11-09
EP3370760A1 (en) 2018-09-12
CN108289935A (zh) 2018-07-17
RU2018120182A (ru) 2019-12-04

Similar Documents

Publication Publication Date Title
ZA201802820B (en) Plasminogen replacement therapy for plasminogen-deficiency
SG10201912416QA (en) Therapeutic agents
ZA201802462B (en) Gene therapy
GB201509893D0 (en) Therapeutic agents
GB201516442D0 (en) Combination therapy
GB201517263D0 (en) Therapeutic agents
IL257976A (en) Combined treatment
GB201512365D0 (en) Novel therapy
ZA201804155B (en) Combination therapy
GB201509885D0 (en) Therapeutic agents
GB201416788D0 (en) Therapeutic applications for pyocins
GB201509888D0 (en) Therapeutic agents
GB201516068D0 (en) Novel therapy
GB201513299D0 (en) Therapeutic agents
PL3244860T3 (pl) Kolumna stołu operacyjnego
GB201505382D0 (en) Novel therapy
GB201521767D0 (en) Therapeutic agents
GB201513151D0 (en) Functional gene replacement therapy
GB201517264D0 (en) Therapeutic agents
SG11201700059WA (en) Therapeutic agent for keratoconjunctive disorder
GB201502209D0 (en) Filovirus therapy
HK1260771A1 (zh) 纤溶酶原缺乏症的纤溶酶原替代疗法
GB201518805D0 (en) Therapy
GB201521755D0 (en) Therapeutic agents
GB201521683D0 (en) Therapeutic agents